The AACR Releases a Call to Action and Key Statistics in Cancer Disparities Progress Report 2024
The AACR issues a call to action and cites progress, needed improvements, and key statistics in their Cancer Disparities Progress Report 2024.
The AACR issues a call to action and cites progress, needed improvements, and key statistics in their Cancer Disparities Progress Report 2024.
Patients with 1 prior line of therapy had improved outcomes on acalabrutinib compared with those who had 2 or more prior lines.
Abstract. Computational methods that simulate tumors mathematically to describe cellular and molecular interactions are emerging as promising tools to simulate the impact of therapy entirely…
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.
First-line treatment with ATO plus ATRA improved EFS over chemotherapy plus ATRA in patients with high-risk APL.
The phase III DREAMM-8 trial evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd) compared with pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide-exposed patients with RRMM after…
A preclinical study suggests the microbiome may be able to influence the severity of GVHD after bone marrow transplant through donor immune cells that recognize…
Rachel Darwin, Senior Manager, Public Relations NCCN Guidelines for Patients earn Hermes Award for electronic media and Communicator Award for medical print content. NCCN Patient…
Cancer immunotherapy is a pillar of clinical oncology but only achieves long-term remissions in a minority of cases. In this issue, van Elsas et al. show…
Most patients with lower-risk myelofibrosis, over a 4-year period, experienced disease progression, as demonstrated by the prospective MOST study.
The FDA has approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent…